Conditions: Asthma
Keywords: Moderate asthma Severe asthma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 558
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.

Detailed description:

Arms:
arm 1: SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily arm 2: budesonide HFA pMDI 160 μg x 2 actuations twice daily

Interventions: intervention 1: Budesonide/formoterol (SYMBICORT) pMDI intervention 2: Budesonide HFA pMDI
Intervention descriptions: intervention 1: SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily intervention 2: Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily

Protocol document: